- Home
- ALLK vs CRVO Comparison
ALLK vs CRVO Comparison
Compare ALLK & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- CRVO
- Stock Information
- Founded
- ALLK 2012
- CRVO 2001
- Country
- ALLK United States
- CRVO United States
- Employees
- ALLK N/A
- CRVO N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ALLK Health Care
- CRVO Health Care
- Exchange
- ALLK Nasdaq
- CRVO Nasdaq
- Market Cap
- ALLK 101.0M
- CRVO 98.3M
- IPO Year
- ALLK 2018
- CRVO N/A
- Fundamental
- Price
- ALLK $1.10
- CRVO $2.02
- Analyst Decision
- ALLK Hold
- CRVO Buy
- Analyst Count
- ALLK 5
- CRVO 8
- Target Price
- ALLK $1.67
- CRVO $38.75
- AVG Volume (30 Days)
- ALLK 306.2K
- CRVO 922.0K
- Earning Date
- ALLK 11-06-2024
- CRVO 11-12-2024
- Dividend Yield
- ALLK N/A
- CRVO N/A
- EPS Growth
- ALLK N/A
- CRVO N/A
- EPS
- ALLK N/A
- CRVO N/A
- Revenue
- ALLK N/A
- CRVO $10,066,550.00
- Revenue This Year
- ALLK N/A
- CRVO $34.17
- Revenue Next Year
- ALLK N/A
- CRVO N/A
- P/E Ratio
- ALLK N/A
- CRVO N/A
- Revenue Growth
- ALLK N/A
- CRVO 116.29
- 52 Week Low
- ALLK $0.54
- CRVO $1.80
- 52 Week High
- ALLK $3.36
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- ALLK 52.99
- CRVO 24.32
- Support Level
- ALLK $1.00
- CRVO $1.80
- Resistance Level
- ALLK $1.11
- CRVO $2.10
- Average True Range (ATR)
- ALLK 0.08
- CRVO 1.45
- MACD
- ALLK 0.00
- CRVO -0.64
- Stochastic Oscillator
- ALLK 47.73
- CRVO 0.95
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.